Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects

Julien Baruteau1,2,3 • Simon N. Waddington3,4 • Ian E. Alexander5,6 • Paul Gissen1,2,7

Received: 12 January 2017 / Revised: 27 April 2017 / Accepted: 28 April 2017
© The Author(s) 2017. This article is an open access publication

Abstract Over the last decade, pioneering liver-directed gene therapy trials for haemophilia B have achieved sustained clinical improvement after a single systemic injection of adeno-associated virus (AAV) derived vectors encoding the human factor IX cDNA. These trials demonstrate the potential of AAV technology to provide long-lasting clinical benefit in the treatment of monogenic liver disorders. Indeed, with more than ten ongoing or planned clinical trials for haemophilia A and B and dozens of trials planned for other inherited genetic/metabolic liver diseases, clinical translation is expanding rapidly. Gene therapy is likely to become an option for routine care of a subset of severe inherited genetic/metabolic liver diseases in the relatively near term. In this review, we aim to summarise the milestones in the development of gene therapy, present the different vector tools and their clinical applications for liver-directed gene therapy. AAV-derived vectors are emerging as the leading candidates for clinical translation of gene delivery to the liver. Therefore, we focus on clinical applications of AAV vectors in providing the most recent update on clinical outcomes of completed and ongoing gene therapy trials and comment on the current challenges that the field is facing for large-scale clinical translation. There is clearly an urgent need for more efficient therapies in many severe monogenic liver disorders, which will require careful risk-benefit analysis for each indication, especially in paediatrics.

Introduction

The liver is a key-regulator of multiple complex metabolic pathways and the hepatocyte is a primary cell type affected in numerous inherited genetic/metabolic diseases (Clayton 2002). Despite a wide range of disease-specific conventional therapies, liver replacement therapies remain a valid strategy and even a potential cure for many monogenic liver disorders due to the ability to restore the defective pathway (Sokal 2006). Liver replacement options include whole or partial organ (Spada et al 2009), or hepatocytes transplantation (Dhawan et al 2006). The shortage of donors, the associated mortality/morbidity and need for immunosuppression, however, often limit this option to severely affected patients and those aged more than 3 months or weighing greater than 5 kg (Haberle et al 2012). In the past decade, liver-directed gene therapy has emerged as a promising alternative to transplantation in monogenic liver disorders.

Presented at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Rome, Italy, September 6–9, 2016

Communicated by: Johannes Häberle

1 Genetics and Genomic Medicine Programme, Great Ormond Street Institute of Child Health, University College London, London, UK
2 Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
3 Gene Transfer Technology Group, Institute for Women’s Health, University College London, London, UK
4 Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
5 Gene Therapy Research Unit, The Children’s Hospital at Westmead and Children’s Medical Research Institute, Westmead, Australia
6 Discipline of Child and Adolescent Health, University of Sydney, Sydney, Australia
7 MRC Laboratory for Molecular Cell Biology, University College London, London, UK
Overview of gene therapy development: reaching maturity

Gene therapy, by providing additional functional gene copies, has been considered for decades as an attractive option for treatment of monogenic disorders (Wirth et al 2013). According to the Gartner hype cycle, a graphical representation depicting the maturity of novel technologies, gene therapy reached its “peak of inflated expectation” in the mid-1990s which was paralleled by a rapid rise in clinical trial activity and the publication of early proof-of-concept studies for genetic and acquired conditions such as adenosine-deaminase deficiency (ADA-SCID) (Blaese et al 1995; Bordignon et al 1995) and brain tumours, respectively (Puumalainen et al 1998). This period of inflated expectation was critiqued in the Orkin-Motulsky report commissioned by the National Institute of Health (Orkin and Motulsky 1995). While acknowledging the extraordinary promise of gene therapy, the report emphasised the need for greater focus on gene transfer technology and the basic science of gene transfer. Soon after, the field plunged into its “trough of disillusionment” following the death of a young adult, Jesse Gelsinger, in a clinical trial for ornithine transcarbamylase (OTC) deficiency (Raper et al 2003). Optimism arising from the subsequent clinical success in the treatment of X-linked severe combined immunodeficiency (SCID-X1) (Cavazzana-Calvo et al 2000) was soon dampened by the occurrence of leukaemia in five out of 20 patients secondary to insertional mutagenesis (Hacein-Bey-Abina et al, 2003a, b; Fischer et al 2010; Mukherjee and Thrasher 2013), causing the death of one participant (Mukherjee and Thrasher 2013). Resultant concerns over gene therapy were further compounded by growing awareness of the challenges imposed by vector-induced immune responses (Mingozzi and High 2007). Disbelief and doubt followed, leading to a decline in financial investment (Ledley et al 2014). In parallel, these adverse events motivated researchers to seek a better understanding of the challenges posed by disease pathophysiology and to develop safer and more efficient vectors. Recent clinical successes in various inherited orphan diseases such as Leber’s congenital amaurosis (Bainbridge et al 2008; Cideciyan et al 2008; Maguire et al 2008), X-linked adrenoleukodystrophy (Cartier et al 2009), metachromatic leukodystrophy (Biffi et al 2013) and haemophilia B (Nathwani et al 2011) and the first market authorisation granted by the European Medicines Agency (EMA) in 2012, to Glybera® for lipoprotein lipase deficiency (Bryant et al 2013), are driving the field up the “slope of enlightenment” and onto the “plateau of productivity”. As a result of this success, various biotechnology companies dedicated to gene therapy development have been created and received substantial financial investment (Cassiday 2014). In parallel, the number of gene therapy-based clinical trials has risen rapidly in recent years (http://www.abedia.com/wiley/(accessed 2017 Jan 06); Ginn et al 2013).

Strategies for hepatocyte-directed gene transfer

A growing toolbox is available for gene transfer, which has been the preferred approach in recent human trials targeting hepatocytes. Various elements in the choice of transgene expression cassette design, mode of delivery and the subset of patients targeted influence the efficacy of gene therapy (Fig. 1).

Parameters of vector delivery

The mode of transgene delivery is crucial: i) local injection allows highly selective expression, but in a limited area. Conversely an intravenous injection allows a broad distribution balanced by non-specificity. Injections in the hepatic artery or the portal vein improve the selectivity but require cannulation with its associated risks (Fumoto et al 2013). Peripheral intravenous delivery provides similar transduction compared to intrahepatic or intraportal routes for AAV vectors (Sarkar et al 2006; Nathwani et al 2007); ii) higher doses of vector achieve greater transduction, but may generate more severe immune responses (Raper et al 2003; Mingozzi and High 2013).

Host pre-sensitisation or acquired immune responses

The immune response against the vector and/or the transgene product might preclude the expected therapeutic effect (Jooss and Chirmule 2003; Zaiss and Muruve 2008; Wold and Toth 2013).

Immune memory of pre-exposure to wild-type viruses can prevent efficient hepatocyte transduction by pre-existing neutralising antibodies and might account for differences in the severity of immune responses observed after systemic injection. Pre-immunisation against the transgene product can occur when the recombinant transgenic protein has been administered. For example, in haemophilia B patients, this can result in the generation of anti-factor IX antibodies when treated by recombinant factor IX (Armstrong et al 2014). Accordingly prior immunisation needs to be carefully considered in clinical trial enrolment criteria.

Acquired immune responses after systemic gene delivery are common. Innate immune responses are triggered by antigen presenting cells such as dendritic cells or macrophages initiating the release of proinflammatory cytokines (interleukins 1 and 6, tumour necrosis factor α (TNFα), type I interferon α and β) via stimulation of Toll-like receptors (TLR). Specific and long-lasting antigen-specific immune responses are mediated by B- and T-cells and involve secretion of neutralising antibodies and CD8+ cytotoxic T lymphocytes, respectively, regulated by the recruitment of helper and regulatory CD4+ T cells. Whatever the viral vector considered, immune responses share various similarities, and must always
be carefully considered (Bessis et al 2004; Tang et al 2006; Annoni et al 2013; Calcedo and Wilson 2013; Basner-Tschakarjan and Mingozi 2014).

**Design and selection of the gene transfer vector**

The *transgene expression cassette* contains i) a transgene, which is commonly a cDNA and may be codon-optimised to achieve higher expression of the transgene product, ii) an enhancer/promoter, the selection of which determines the level of transgene expression, cell-type restricted specificity of expression and also influences the risk of insertional mutagenesis, iii) various pre- and/or post-regulatory elements to stabilise transgene mRNA and therefore increase the yield of transgene product, e.g. addition of an intron downstream of the promoter containing a bacterial replication origin (Lu et al 2017) or the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (Lipshutz et al 2003), respectively.

**Several options are available to deliver the transgene expression cassette to the target cell/organ**

Injection of *naked DNA*, either as *plasmids* (Doenecke et al 2010; Oishi et al 2016) or *mini-circles* (Viecelli et al 2014; Hou et al 2016; Wu et al 2016), is a simple mode of transgene delivery which lends itself to local delivery and is relatively non-immunogenic compared to some viral vector approaches (Wolff and Budker 2005). Mini-circles are devoid of plasmid backbone DNA; this may enhance transgene expression by overcoming heterochromatin formation and avoiding inflammation triggered by bacterial DNA (Mayrhofer et al 2009). These approaches allow easy production of therapeutic material with a good safety profile and capable of eliciting long-lasting transgene expression in post-mitotic tissues (Wolff and Budker 2005; Kay et al 2010). These approaches have been employed in ~17% of gene therapy trials so far (http://www. abedia.com/wiley/(accessed 2017 Jan 06)). The hydrodynamic injection technique, developed in small animal models, consists of injecting DNA plasmids or mini-circles in a large vehicle volume to flood the liver with pressurised DNA solution; this disrupts vascular endothelium, and allows high levels of transgene expression in small or large animal models (Liu et al 1999). Although hydrodynamic injections are difficult to translate to humans, intravascular hydrodynamic procedures with partial catheterisation for liver-directed gene delivery have shown some success in large animals (Sendra et al 2016; Yokoo et al 2016). However, current translatable options of non-viral approaches remain limited. Therefore viral vectors, acting as Trojan horses to increase transduction efficiency, are frequently considered.

**Non-viral vectors** are synthetically produced biological particles, in which the transgene is encapsulated, or complexed, and released at the target site. Various engineered nanoparticles exist, e.g. liposomes or/and polymers (Chira
et al 2015). These options have several advantages: easy production, no restriction of the transgene size, and a reliable safety profile. Limitations are the stability of these particles, cellular uptake and a limited ability to achieve long-lasting transgene expression (Elsabahy et al 2011). These are therefore suboptimal delivery vehicles for liver-directed clinical trials.

**Virus-derived vectors** represent an attractive approach based on their relatively efficient transduction human cells. The main vectors that have been used in clinical trials are derived from adenoviruses (21%), retroviruses (excluding lentiviruses) (19%), adeno-associated viruses (7%) and lentiviruses (6%) (http://www.abedia.com/wiley/(accessed 2017 Jan 06)).

**Retroviral vectors**

*Gamma-retroviruses* such as murine leukaemia viruses (MLVs) are RNA viruses encoding *gag*, *pol* and *env* genes flanked by long terminal repeats (LTRs), which carry enhancers/promoter elements and are required for integration. After transduction of the target cell, reverse-transcription generates a double-stranded DNA copy of the proviral genome, which then integrates in the host genome providing long-term transgene expression. Gamma-retroviruses are unable to transduce non-dividing cells as the nuclear membrane prevents retroviral vectors from entering the nucleus (Miller et al 1990). This explains why this vector is more often considered for *ex vivo* gene therapy in which cultured target cells are stimulated to replicate and then transduce. *Lentiviruses* are a class of retroviruses, the most widely known of which is HIV1. Lentiviral vectors are able to transduce dividing and non-dividing cells, which broadens their application. Retroviral vectors have relatively large transgene capacities (7.5 kilobases (kb)) (Verma and Somia 1997). In fact payloads exceeding 14 kilobases have been packaged into lentiviral vectors (Counsell et al, 2017).

**Clinical applications and limitations**: In an early gene therapy trial, a γ-retroviral vector was used in an *ex vivo* approach with autologous hepatocytes in five patients with homozygous familial hypercholesterolemia. This showed a mild improvement of lipid profiles in two patients with a very low rate of stable engraftment at 4 months after gene therapy (Grossman et al 1994; Grossman et al 1995). Several limitations emerged from this trial: i) the need for two invasive procedures, i.e. the surgical resection of a liver lobe to obtain sufficient primary hepatocytes for transduction as hepatocytes cannot be expanded in culture and re-injection of transduced hepatocytes into the portal circulation via a local catheter, with the associated risks of venous thrombosis, catheter misplacement and haemorrhage (Grossman et al 1994; Raper et al 1996). The efficiency with which hepatocytes were harvested and transduced was low, 30% and 10% respectively (Grossman et al 1995). Protocols for lentiviral-mediated gene therapy have improved with *in vitro* transduction efficacy reaching 90% in non-human and human hepatocytes (Nguyen et al 2009). Hepatocyte transplantation, however, remains relatively inefficient and variable, likely due to poor engraftment, limited persistence of engrafted hepatocytes and the lack of a proliferative advantage (Gramignoli et al 2015).

Retroviral-mediated in *vivo* gene therapy was well tolerated when vector was administered intravenously in haemophilia A patients, but no significant clinical benefits were observed (Powell et al 2003). Preclinical studies failed to accurately predict the therapeutic dose and it was suggested that retroviral vectors were unable to transduce non-dividing hepatocytes (Chuah et al 2004). Therefore, alternative viral vectors, including lentiviral vectors, have been developed for treatment of hemophiliacs. Indeed two promising approaches with lentiviral vectors are in preclinical development: i) systemic lentiviral-mediated liver-restricted gene therapy in a dog model of haemophilia B, which showed long-term efficacy, induction of liver tolerogenic properties in stimulating CD4+CD25+FoxP3+ regulatory T cells and no evidence of genotoxicity in mice (Cantore et al 2015). The immune tolerance is of particular interest for patients with anti-FIX inhibitors, who are currently excluded from gene therapy trials; ii) *ex vivo* transduction of haematopoietic stem cells (HSC) in mice with successful *FIX* gene expression to target cells of the erythroid (Chang et al 2008) or the megakaryocyte lineage (Chen et al 2014). A lentiviral vector is currently in preclinical development for haemophilia B (Dolgin 2016). Lentiviral vectors are able to accommodate large transgenes such as *FVIII* gene for haemophilia A (Kuether et al 2012). Lentiviral-mediated liver-directed *ex vivo* gene therapy has been successfully reported in a pig model of tyrosinaemia 1 using the selective advantage of *Fah+/−* modified hepatocytes (Hickey et al 2016).

The risk of insertional mutagenesis has been reported with retroviral vectors (Cavazzana-Calvo et al 2000; Mukherjee and Thrasher 2013), however, there is evidence that the risk is lower with lentiviral vectors (Kotterman et al 2015). To improve safety, self-inactivating (SIN) vectors have been developed in which LTR enhancer/promoter elements in the U3 region have been deleted (Miyoshi et al 1998; Zufferey et al 1998). This, however, does not completely eliminate the risk of insertional mutagenesis as heterologous enhancer-promoter elements still need to be included in vector constructs. Genotoxicity has been observed after foetal injections of non-primate and primate SIN-lentiviral vectors (Nowrouzi et al 2013; Condiotti et al 2014). So far, more than 125 patients over 14 years have been treated with haematopoietic stem cells or T cells transduced by lentiviral vectors with no oncogenic event reported (Cartier et al 2009; Biffi et al 2013; McGarrity et al 2013; Booth et al 2016). Another approach relies on the mutation of the integrase protein to generate non-
integrating or integration-deficient lentiviral vectors (Nightingale et al 2006; Philippe et al 2006; Yanez-Munoz et al 2006), which have shown long-lasting gene expression in non-dividing tissues (Apolonia et al 2007; Rahim et al 2009) and phenotype correction in mice with haemophilia B (Suwanmanee et al 2014).

Adenoviral vectors

Adenoviruses are non-enveloped double-stranded DNA viruses with a large 36 kb genome and are capable of transducing dividing and non-dividing cells. In humans, a common target is epithelial cells of the respiratory or gastrointestinal tracts causing mild upper respiratory tract infection, gastroenteritis, or asymptomatic seroconversion. More than 55 serotypes are described but most vectors are derived from endemic serotypes 2 and 5 (Piccolo and Brunetti-Pierri 2014). The seroprevalence against the most common serotype (Adenovirus 5) is high with neutralising antibodies in 45–80% (Kotterman et al 2015). Adenoviruses elicit a sustained innate and cytotoxic-mediated immunity, which leads to the clearance of transduced cells (Tang et al 2006; Thaci et al 2011). Neither adenoviruses nor adenoviral vectors have been associated with genotoxicity in humans (Stephen et al 2010). Adenoviral vectors can accommodate large transgenes, which remain episomal in the transduced cell but enable a long-lasting transgene expression in quiescent or dividing cells. In animal models, adenoviral vectors exhibit strong liver tropism through interaction with coagulation factor X (Kalyuzhniy et al 2008; Vigant et al 2008; Waddington et al 2008).

Clinical applications and limitations

In adenoviruses, expression of genes occurs in two early and late phases. The early phase is mediated by E1-E4 transcription units. Proteins encoded by E1 are essential for viral gene expression and DNA replication. Late gene expression is mediated by an internal promoter (Benihoud et al 1999). First-generation adenoviral vectors have E1 or E1-E3 regions removed and are theoretically replication-defective. However, these vectors keep a mild “leaky” expression of viral genes and are still able to synthesise some viral proteins, likely due to E1-like protein in the target cells (Zhang et al 1998; Lozier et al 1999). Moreover, the immunogenic properties of first-generation adenoviral vectors cause severe acute innate and chronic adaptive immune responses in small and large animal models (Yang et al 1994). To reduce this immune response, deletion of transcription units E1/E2/E3, E1/E4/E3, E1/E2/E3/E4 has been introduced (Alba et al 2005). Only the last combination achieved a reduction of vector toxicity, but with a reduced duration of the transgene expression (Gao et al 1996; Raper et al 1998; Andrews et al 2001). A second generation (E1- and E4-deleted) adenoviral 5 vector was used for the OTC deficiency trial, in which Jesse Gelsinger, a young adult with late-onset OTC deficiency enrolled in the highest dose group, died after developing a fatal acute toxic reaction with fulminant inflammatory response and multi-organ failure hours after the injection of the vector (Raper et al 2003). It has been hypothesised that this was caused by an innate immune response with a cytokine storm triggered by antigen presenting cells against capsid proteins (Raper et al 2003). The reason for severity of this immune response remains unclear as another patient injected with the same dose exhibited only mild flu-like symptoms. A genetic predisposition or an immune memory response caused by pre-exposure to adenoviruses might partly explain this discrepancy (Wilson 2009). In this trial, safety issues were surprisingly not dose-related and had not been predicted to this extent by animal studies (Raper et al 2002). Furthermore, no significant clinical benefit was observed (Raper et al 2002).

To limit this immune response, “gutless” or helper-dependent adenoviral vectors (HD-Ad) have been designed by deletion of all coding regions except the ITRs and the packaging signal (Ψ) required for the encapsidation of the adenoviral genome, which have been replaced by the transgene cassette and stuffer DNA (Alba et al 2005). This new generation of vectors have shown an improved safety profile, exhibiting a reduced acute innate immune response and an absence of chronic toxicity. In first-generation adenoviral vectors, the “leaky” expression of the remaining viral genes have a direct cytotoxic effect and triggers an adaptive cellular immune response directed against the transduced cell, which in turn results in transient transgene expression and chronic toxicity (Brunetti-Pierri and Ng 2011). As HD-Ad do not contain any viral genes, this late toxicity is not observed, which allows a long-term transgene expression as observed in small (Kim et al 2001; Toietta et al 2005) and large animal models (Morral et al 1999; Brunetti-Pierri et al 2006). This has allowed successful long-term phenotypic correction of various liver monogenic disorders (Brunetti-Pierri and Ng 2011), among which haemophilia A (Reddy et al 2002; Hu et al 2011), haemophilia B (Ehrhardt and Kay 2002), OTC deficiency (Mian and Lee 2002), glycogen storage disease 1A (Koebel et al 2007), Criggler-Najjar syndrome (Schmitt et al 2014), primary hyperoxaluria type 1 (Castello et al 2016), acute intermittent porphyria (Unzu et al 2013), phenylketonuria (Cerreto et al 2012), familial hypercholesterolaemia caused by mutations in the LDLR (Nomura et al 2004) and ApoE genes (Belalcazar et al 2003) in rodents, haemophilia A (Brown et al 2004; McCormack et al 2006) and B (Ehrhardt et al 2003; Brunetti-Pierri et al 2005), glycogen storage disease type 1 (Crane et al 2012) in dogs, and haemophilia A and B in primates.
B and Pompe disease (Rastall et al 2016) in non human primates.

However, the acute innate immune response directed against capsid proteins is not abolished in HD-Ad vectors (Muruve et al 2004). For both first-generation and helper-dependent adenoviral vectors, this acute immune response is dose-dependent and can be lethal at high doses in non human primates (Morrall et al 2002; Brunetti-Pierri et al 2004). Differences in the severity of the immune response between species have emerged due to variable interactions between blood cells and hepatic microarchitecture such as size of liver sinusoidal fenestration (Piccolo and Brunetti-Pierri 2014). The activation of this innate immunity is multifactorial. Adenoviral particles can trigger the immune response by binding to Toll-like receptors (TLR2, TLR9) at the surface of antigen presenting cells, and/or activate the complement cascade in the bloodstream (Kiang et al 2006; Zhu et al 2007). Kupffer cells recognise the adenoviral capsid either via antibody-mediated opsonisation or in binding complement factors. Kupffer cells develop a pro-inflammatory state with necrotic death, which further disseminate the immune response (Schiedner et al 2003).

In vivo HD-Ad mediated gene therapy has been performed in one patient in a phase I trial for haemophilia A. After a single intravenous low-dose injection, the patient developed flu-like symptoms with transient fever, chills, back pain, headache and transient biological abnormalities including thrombocytopenia, laboratory features of disseminated intravascular coagulopathy, increase in interleukin 6 levels, and elevated liver transaminase levels peaking at 7 days (marked as grade 3 liver toxicity) (Chuah et al 2004; White and Monahan 2005; Chandler and Venditti 2016). The patient expressed 1% FVIII for some months but the trial was halted for safety reason although biological abnormalities came back to normal within 19 days. Unfortunately, this trial has not been published in a peer-reviewed format and few details are available (Piccolo and Brunetti-Pierri 2014). The cause of these symptoms remains unclear although, as supposed for the OTC trial involving Jesse Gelsinger, the innate immune response against the adenoviral capsid and its subsequent release of cytokines has been suspected (Chuah et al 2004). Contamination by an adenoviral helper virus remains a possible explanation (Chuah et al 2003).

Despite limited application for liver monogenic disorders, adenoviral vectors have been successfully used for oncolytic virotherapy (Rosewell Shaw and Suzuki 2016) and vaccination (Majhen et al 2014), which exploits adenoviral immunogenicity.

Adeno-associated viral vectors

Adeno-associated viruses (AAV) are non-enveloped, single-stranded DNA viruses that belong to the Dependovirus genus and the Parvoviridae family. Initially identified as a contaminant of an adenoviral preparation (Atchison et al 1965), the virus was later shown to require co-infection with a helper virus to replicate. In the absence of helper virus, AAV can enter target cells and establish latent infection through genomic integration and/or formation of episomes. AAV is widely considered non-pathogenic and has yet to be definitively linked to disease causation. AAVs can transduce dividing and non-dividing cells. The seroprevalence against the most common serotype AAV2 is 40–60% (Lous Jeune et al 2013). AAV virions consist of an icosahedral capsid of approximately 22 nm in diameter enclosing a 4.7 kb single-stranded genome. The genome is flanked by two 145 nucleotide inverted terminal repeats (ITRs) containing all of the necessary cis-acting functions for proviral rescue, genome replication and packaging. The viral genome encodes 4 Rep proteins required for proviral rescue and genome replication, and three viral proteins VP1, VP2 and VP3, which assemble to form the capsid (Fig. 2A) (Samulski and Muzyczka 2014). Some, but not all, AAV capsid serotypes (Earley et al 2017) require expression of an assembly-activating protein (AAP) encoded by an alternative reading frame of the Cap gene and providing scaffolding activity (Naumer et al 2012). Numerous AAV serotypes have been isolated from humans, non-human primates and other species, with the viral capsid determining species and target cell tropism through interaction with a diversity of cell surface receptors/co-receptors and intracellular trafficking pathways that remain incompletely understood. A multi-serotype AAV receptor has been recently identified (Pillay et al 2016), but its precise role in uptake and trafficking has yet to be elucidated (Summerford and Samulski 2016). For example, AAV3B uses the human hepatocyte growth factor (hHGF) receptor, which restricts transduction to primates and especially to the liver (Vercauteren et al 2016).

Since 2004, AAV vectors have emerged as the leading candidates for gene therapy in monogenic liver disorders with the best accepted benefit-risk ratio (Dolgin 2016). Therefore, the following sections focus on this gene transfer approach detailing clinical successes and current limitations.

AAV2 is the most widely studied serotype and was the first to be vectorized. To generate a recombinant AAV vector the native Rep and Cap genes are removed and replaced by a transgene expression cassette with only the flanking ITRs retained (Fig. 2A). Recombinant virus is produced by supplying Rep and Cap and necessary adenoviral helper functions in trans. A major development in AAV vector technology was the demonstration that recombinant AAV2 genomes can be cross-packaged, or pseudo-serotyped, with the capsids from other AAV serotypes (Rabinowitz et al 2002). This has dramatically broadened the cell types that can be efficiently targeted with AAV vectors. For example, pseudo-serotyping a recombinant
AAV2 vector genome with the AAV8 capsid (designated AAV2/8) enhances tropism for hepatocytes, particularly in the mouse (Fig. 2B). AAV vectors bind to target cells via specific receptors and co-receptors that differ in a capsid-dependent manner and are taken up by endocytosis or macropinocytosis, before being trafficked to the nucleus for capsid uncoating. The uncoated genomes can remain in the nucleus in single-stranded form, be converted to double-stranded episomes or undergo genomic integration (Fig. 3) (Berry and Asokan 2016). Conversion of input single-stranded genomes to double-stranded transcriptionally active forms occurs with variable efficiency in different cell types. Self-complementary (sc) vectors differ from single-stranded vectors (ss) in that they contain a self-complementary transgene cassette that folds back on itself to form double-stranded DNA thereby bypassing the requirement for second strand synthesis, which is considered as a rate-limiting step for transgene expression. As a consequence the packaging size of the transgene cassette in scAAV is reduced by half (McCarty 2008).

Clinical successes of liver-directed AAV-mediated gene therapy

A rapidly increasing number of publications have reported proof-of-concept for AAV-based gene therapy in animal models for various inherited liver disorders including urea cycle defects, organic acidurias, phenylketonuria, glycogen storage disease type Ia, long chain fatty acid oxidation disorders, homozygous familial hypercholesterolemia, primary hyperoxaluria type I and progressive familial intrahepatic cholestasis (Hastie and Samulski 2015; Junge et al 2015).

In parallel, pioneering trials have been conducted since the 2000s, two of which targeted haemophilia B. This disease is an attractive target for gene therapy as an increase in plasma factor IX (FIX) of as little as 1% can confer significant phenotypic improvement. Haemophilia B is a burden in public healthcare systems with an annual cost of $300,000 for severely affected patients (Angelis et al 2015).

In 2004, a ssAAV2.ApoE/hAAT/hFIX vector, administered via the hepatic artery, showed a transient increase of plasma
FIX from <1% to 3–11% over 4 weeks followed by a gradual decline over 4–8 weeks concomitant with transient asymptomatic rise in transaminases levels (Manno et al 2006), later recognised as T cell-mediated cytotoxicity (Mingozzi et al 2007).

In 2009, Nathwani et al, injected a scAAV 2/8.LP1.hcoFIX vector via a peripheral intravenous route and elicited a long-lasting (>5 years) increase of plasma FIX from <1% to 1–8% (Nienhuis et al 2016). Elevated transaminases occurring 7–10 weeks post-injection resolved after an oral course of corticosteroids, but were associated with a decrease of 50–70% in plasma FIX levels attributable to a cellular immune response against capsid epitopes (Nathwani et al 2014).

D’Avola et al, recently reported results of a trial of scAAV2/5.hAAT.hcoPBGD vector in acute intermittent porphyria with peripheral intravenous delivery. No vector-related safety issues were reported and the rate of disease-related hospitalisation decreased, potentially as a consequence of closer metabolic follow-up. No change was observed in the levels of metabolic biomarkers (D’Avola et al 2016).
might be explained by a less efficient liver transduction mediated by AAV5 relative to AAV8 and a reduced expression of the episomal transgene compared to the endogenous gene of interest (Baruteau et al 2017). However, no liver biopsy data was available to address this assumption.

Preliminary reports from ongoing clinical trials have confirmed Nathwani’s promising results for haemophilia B. After a single intravenous injection of AAV vectors with different capsids encoding the FIX gene or its Padua FIX variant, which contains a gain-of-function mutation, reported stabilised plasma FIX levels have ranged from 3 to 8% in the AMT-060 trial sponsored by Uniqure (Miesbach et al 2016) and the DTX-101 sponsored by Dimension Therapeutics (http://dimensiontx.com) to 20–44% in the high-dose cohort of the BAX 335 trial sponsored by Shire (Monahan et al 2015) and in the SPK-9001 trial sponsored by Spark Therapeutics/Pfizer (George et al 2016). In a haemophilia A gene therapy trial, BioMarin reported plasma factor VIII (FVIII) from 4 to 60% in the high-dose group of the BMN 270 trial (Pasi et al 2016) (Table 1). Importantly, endogenous FVIII is primarily secreted by endothelial cells (Fahs et al 2014). All the AAV-based trials have so far involved only adult patients, who had an undetectable baseline titre of neutralising antibodies to the capsid (usually accepted cut-off of 1/5 serum dilution). Monogenic liver disorders in AAV-based gene therapy development pipelines of pharmaceutical companies include OTCD, glycogen storage disease type Ia, citrullinemia type I, phenylketonuria, Wilson disease, methylmalonic acidaemia and Crigler-Najjar syndrome (Kattenhorn et al 2016).

Current challenges

Insertional mutagenesis

Despite more than 170 AAV-based human trials approved, ongoing or completed (http://www.abedia.com/wiley/ (accessed 2017 Jan 06)), no tumorigenic events have been reported so far. AAV vector genome mainly persists as episome in the transduced cell with a relatively low proportion of vector genomes undergoing integration preferentially in transcriptionally active genes, damaged DNA or enriched CpG islands (McCarty et al 2004). Experiments in neonatal mice have identified an increased risk of hepatocellular carcinoma (HCC) after systemic injection. This risk increased with the enhancer/promoter activity, younger age at time of injection and vector dose (Donsante et al 2007; Chandler et al 2015; Chandler et al 2017). Analysis of integration sites identified a rodent-specific hotspot in the Rian locus. Integration studies from human trials have not shown such hotspots, but rather a genome wide integration pattern involving neither HCC-related genes nor the human Rian homologue, Dlk1-Dio3 (Kaeppel et al 2013; Gil-Farina and Schmidt 2016).

Controversies remain regarding the possible insertional mutagenic effects of wild type AAV. Detection of a clonal expansion of wild type AAV2 sequences in 11/193 HCCs within HCC-related genes (Nault et al 2015) initiated a passionate and unresolved debate about “driver” or “passenger” cancer-related genetic modifications (Berns et al 2015; Buning and Schmidt 2015). The cumulative safety experience with the rapidly growing number of AAV-based trials targeting the human liver, combined with the low rate of HCC-associated AAV integrations despite the high seroprevalence of wild type AAV in the human population (e.g. >50% for AAV2) (Thwaites et al 2015) are consistent with a favourable safety profile of AAV vectors. Nevertheless the findings of Nault et al warrant further studies and mandate close monitoring in ongoing human trials.

Immune response

After vector delivery, non-specific innate immunity triggers both type I interferon signalling involved in transgene silencing (Suzuki et al 2013) and the release of pro-inflammatory cytokines (Jayandharan et al 2011). Highly-specific and long-lasting adaptive immunity generates B- and T-cell responses against the capsid and/or the transgene product (Fig. 3). Neutralising antibodies against the capsid, even at low titers, inhibit transduction after systemic delivery (Jiang et al, 2006a, b). This barrier is of substantial concern to gene therapy development and the ongoing liver-directed trials are recruiting only seronegative patients without neutralising antibodies against the AAV capsid. This narrows the target population as the seroprevalence against liver-specific AAV serotypes ranges from 20 to 30% for AAV5, 6 and 8 to 50–60% for AAV2 (Louis Jeune et al 2013). Cross-reactivity between serotypes is commonly >50% (Boutin et al 2010). This seroprevalence varies depending on geographic origin (Calcedo et al 2009) and age. Neonates receive maternal antibodies by transplacental transfer and acquired with maternal milk, which are lost over the first months of life. Thereafter, seroprevalence remains negligible until 3 years of age after which the seroconversion rate progressively increases until adulthood (Calcedo et al 2011; Li et al 2012).

Human CD8+ T-cell mediated immune responses are involved in AAV hepatotoxicity and were initially encountered during the first haemophilia B trial (Manno et al 2006). Capsid epitopes, presented via the major histocompatibility complex I (MHC1), were shown to drive expansion of a pre-existing pool of CD8+ memory T cells acquired during a previous co-infection of wild type AAV and helper virus (adenovirus or herpes virus for example). This response was dose-dependent (Mingozzi and High 2013) and could be stimulated by alternate capsids (Mingozzi et al 2007).
Table 1  Clinical trials of gene therapy products for liver monogenic disorders. Intraportal and intrahepatic routes of administration relate to injection on the portal vein and the hepatic artery respectively. FVIII: factor VIII; FIX: factor IX; HD-adenovirus: helper-dependent adenovirus; LDL: low density lipoprotein; MoML: Moloney murine leukaemia virus; NA: not applicable; OTC: ornithine transcarbamylase; PBGD: porphobilinogen deaminase. Information sources: clinicaltrial.gov (accessed 06/01/2017) and company websites. If the date of the start of the trial was not available in clinicaltrials.gov website, the date of publication of the results is mentioned. The list of trials announced for 2017 is indicative and does not pretend to be exhaustive.

| Year (start of trial) | Viral vector | Disease | Product | Therapeutic | Sponsor | Route | Dose | Number of treated patients | Status | Reference | Clinicaltrial.gov identifier |
|-----------------------|-------------|---------|---------|-------------|---------|--------|------|-----------------------------|--------|-----------|-----------------------------|
| 1992 MoMLV Retrovirus 5 | Homozygous familial hypercholesterolaemia | NA | LDL receptor gene | University of Michigan Ann Arbor | Intraportal (Ex vivo approach) | 1 to 3.3 × 10^9 hepatocytes | 5 | Terminated | Grossman et al 1994, Grossman et al 1995, Raper et al 1996 | NCT00004809 |
| 1998 Adenovirus 5 | Ornithine transcarbamylase deficiency | NA | OTC gene | University of Pennsylvania | Intrahepatic | 2 × 10^9 to 6 × 10^11 vg/kg | 18 | Terminated | Raper et al 2003 | NCT00004498 |
| 1999 AAV2 | Haemophilia B | NA | Factor IX gene | NA | Intramuscular | 2 × 10^11 to 1.8 × 10^12 vg/kg | 8 | Terminated | Kay et al 2000, Manno et al 2003 | NA |
| 2003 MoMLV Retrovirus | Haemophilia A | NA | FVIII gene | Chiron | Intravenous | 2.8 × 10^7 to 4.4 × 10^8 vg/kg | 13 | Terminated | Powell et al 2003 | NA |
| 2004 HD-Adenovirus | Haemophilia A | NA | FVIII gene | GenStar | Intravenous | 4.3 × 10^8 vg/kg | 1 | Terminated | Chuah et al 2004 | NA |
| 2004 AAV2 | α1-antitrypsin | NA | hAAT | University Massachusetts | Intramuscular | 2.1 × 10^12 to 6.9 × 10^13 vg | 12 | Terminated | Flotte et al 2004, Brantly et al 2006 | NCT00377416 |
| 2004 AAV2 | Haemophilia B | NA | Factor IX gene | Avigen | Intravenous | 8 × 10^10 to 2 × 10^12 vg/kg | 7 | Terminated | Manno et al 2006 | NCT00076557 |
| 2006 AAV1 | α1-antitrypsin | NA | hAAT | University Massachusetts | Intramuscular | 6.9 × 10^10 to 2.4 × 10^12 vg/kg | 9 | Terminated | Brantly et al 2009 | NCT00430768 |
| 2009 AAV2/8 | Haemophilia B | NA | Factor IX gene | St Jude Children's Hospital | Intravenous | 2 × 10^11 to 2 × 10^12 vg/kg | 10 | Recruiting | Nathwani et al 2014 | NCT00979238 |
| 2010 AAV1 | α1-antitrypsin | NA | hAAT | Applied Genetic Technologies | Intramuscular | 2 × 10^12 to 6 × 10^12 vg/kg | 9 | Terminated | Flotte et al 2011 | NCT01054339 |
| 2012 AAV2/8 | Haemophilia B | BAX 335 Padua mutant factor IX gene | Shire | Intravenous | 2 × 10^11 to 3 × 10^12 vg/kg | 6 | Terminated | Monahan et al 2015 | NCT01687608 |
| 2014 AAV2/5 | Acute intermittent porphyria | NA | PBGD gene | Digna Biotech | Intravenous | 5 × 10^11 to 1.8 × 10^12 vg/kg | 8 | Terminated | D'Avola et al 2016 | NCT02082860 |
| 2015 Engineered AAV | Haemophilia B | SPK-9001 Padua mutant factor IX gene | Spark Therapeutics | Intravenous | 5 × 10^11 vg/kg (Low dose) | 7 | Recruiting | George et al 2016 | NCT02484092 |
| 2015 AAV2/5 | Haemophilia B | AMT-060 Factor IX gene | Uniqure Biopharma | Intravenous | 5 × 10^12 to 2 × 10^13 vg/kg | 5 | Recruiting | Miesbach et al 2016 | NCT02396342 |
| 2016 AAV2/rh10 | Haemophilia B | DTX101 Factor IX gene | Engineered AAV | Intravenous | 5 × 10^12 to 2 × 10^13 vg/kg | 7 | Recruiting | George et al 2016 | NCT02484092 |
| 2017 Engineered AAV | Haemophilia B | SPK-9001 Padua mutant factor IX gene | Spark Therapeutics | Intravenous | 5 × 10^11 vg/kg (Low dose) | 7 | Recruiting | George et al 2016 | NCT02396342 |
| 2017 Engineered AAV | Haemophilia B | AMT-060 Factor IX gene | Uniqure Biopharma | Intravenous | 5 × 10^12 to 2 × 10^13 vg/kg | 5 | Recruiting | Miesbach et al 2016 | NCT02396342 |
| 2017 Engineered AAV | Haemophilia B | DTX101 Factor IX gene | Engineered AAV | Intravenous | 5 × 10^12 to 2 × 10^13 vg/kg | 7 | Recruiting | George et al 2016 | NCT02396342 |
| Year (start of trial) | Viral vector | Disease | Product | Therapeutic | Sponsor | Route | Dose | Number of treated patients | Status | Reference |
|----------------------|--------------|---------|---------|-------------|---------|-------|------|-----------------------------|--------|-----------|
| 2016                 | AAV2/5       | Haemophilia A | BMN 270 | Factor VIII gene | Dimension Therapeutics BioMarin Pharmaceuticals Sangamo Biosciences | Intravenous | 1.6 × 10e12 to 6 × 10e16 vg/kg | Undisclosed | 9 | Recruiting | clinicaltrials.gov NCT02576795 |
| 2016                 | AAV2/6       | Haemophilia B | SB-FIX | Factor IX integrating in the albumin locus via Zinc-finger-nuclease Sangamo Biosciences | Intravenous | 4 × 10e12 to 5 × 10e13 vg/kg | Undisclosed | Recruiting | clinicaltrials.gov NCT02695160 |
| Announced for 2017   | AAV2/8       | Homozygous familial hypercholesterolaemia | RGX-501 | LDL receptor gene | University of Pennsylvania/Regenxbio | Intravenous | 2.5 × 10e11 to 7.5 × 10e12 vg/kg | Undisclosed | Recruiting | clinicaltrials.gov NCT02651675 |
| Announced for 2017   | Engineered AAV AAV2/8 | Haemophilia A | DTX301 | OTC gene | Dimension Therapeutics | Intravenous | 2 × 10e12 to 2 × 10e13 vg/kg | Undisclosed | Recruiting | clinicaltrials.gov NCT02991144 |
| Engineered AAV AAV2/8 | Haemophilia A | SPK-8011 | Factor VIII gene | Spark Therapeutics | Intravenous | Undisclosed | Undisclosed | Recycling | clinicaltrials.gov NCT03003533 |
| Engineered AAV AAV2/8 | Haemophilia A | GO-8 | Factor VIII gene | University College London | Intravenous | 6 × 10e11 to 6 × 10e12 vg/kg | Undisclosed | Not yet recruiting | clinicaltrials.gov NCT03001830 |
| AAV2/6               | Haemophilia A | BAX-888 | Factor VIII gene | Shire Dimension Therapeutics/Bayer Sangamo Biosciences | Intravenous | Undisclosed | Undisclosed | Recruiting | clinicaltrials.gov NCT03003533 |
| AAV2/6               | Haemophilia A | DTX201 | Factor VIII gene | Shire Dimension Therapeutics/Bayer Sangamo Biosciences | Intravenous | Undisclosed | Undisclosed | Recruiting | clinicaltrials.gov NCT03001830 |
| AAV2/8               | Haemophilia A | SB-525 | Factor VIII gene integrating in the albumin locus via Zinc-finger-nuclease Sangamo Biosciences | Intravenous | Undisclosed | Undisclosed | Recruiting | clinicaltrials.gov NCT03001830 |
| AAV2/8               | Mucopolysaccharidosis VI | MeuSIX | ARSB gene | Audentes Therapeutics | Intravenous | Undisclosed | Undisclosed | Recruiting | clinicaltrials.gov NCT03001830 |
| AAV2/8               | Crigler Najjar | AT342 | UGT1A1 gene | Audentes Therapeutics | Intravenous | Undisclosed | Undisclosed | Recruiting | clinicaltrials.gov NCT03001830 |
Hepatic tolerogenic properties involve the proliferation of a specific T cell subset, CD4+CD25+FoxP3+ Treg cells (Cooper et al. 2009) interacting with Kupffer cells (Breous et al. 2009). Expansion of these cells suppresses cytotoxic immunity against AAV-transduced hepatocytes and induces immunotolerance, e.g. after neonatal injection (Shi et al. 2013). Regulatory tolerance requires continuous antigen presentation and has been successfully induced with transgenic proteins (Shi et al. 2013; Perrine et al. 2016). In contrast, capsid proteins are rapidly eliminated in the proteasome (Berry and Asokan 2016) and therefore very unlikely to induce tolerance. Various approaches aim to overcome these unwanted immune responses in order either to treat seropositive patients or to prevent sensitisation against the AAV capsid, which would allow reinjection in the future. Capsid modification targeting specific epitopes can evade host immunity (Tseng and Agbandje-McKenna 2014). Any strategy optimising the transduction of the target organ such as optimised expression cassette design, or capsid modifications will in turn decrease the amount of vector required for a similar effect. The decrease in vector dose will further reduce the immune response (Mingozzi and High 2011). Various protocols involving transient immunosuppression have been proposed in large animal models and humans. These include plasmapheresis (Monteilhet et al. 2011; Chicoine et al. 2014), monoclonal antiCD20 antibody (rituximab) (Mingozzi et al. 2013; Corti et al. 2014), non-depleting antiCD4 antibody (McIntosh et al. 2012), sirolimus (Corti et al. 2014), cyclosporine A (McIntosh et al. 2012; Mingozzi et al. 2012), tacrolimus with mycophenolate mofetil (Chicoine et al. 2014), proteasome inhibitors, e.g. bortezomib (Monahan et al. 2010) and corticosteroids (Flanigan et al. 2013; Chicoine et al. 2014; Nathwani et al. 2014). One currently controversial strategy to blunt anti-capsid immune responses, is to co-inject “full” AAV vectors and “empty” capsids as decoys, in an attempt to competitively bind existing antibodies (Tse et al. 2015).

Optimised targeting

The ideal AAV vector would exclusively transduce the desired target cells. This would limit unwanted immune responses, avoid ectopic transgene expression and further reduce the already low risk of germline transmission. Extensive capsid-focused research based on high-throughput in vitro and in vivo screening of “libraries” of new capsid variants is ongoing in order to optimise vectors for specific applications. These “accelerated evolution” libraries are generated using strategies such as error-prone PCR (Kotterman and Schaffer 2014; Deverman et al. 2016) and “capsid shuffling” with random cut-paste sequences of wild type cap genes (Kay 2011; Louis Jeune et al. 2013; Choudhury et al. 2016). This approach is paying off by generating re-engineered AAV variants with increased transduction efficiency in primary human hepatocytes (Lisowski et al. 2014).

Germline transmission

The risk for this phenomenon is difficult to quantify. Insertion of AAV sequences into the genome of a gamete could potentially interfere with normal foetal development or promote tumorigenicity in the progeny. So far adult patients enrolled in AAV trials with systemic delivery have been required to use contraception. Vector sequences have been detected transiently in semen of
treated patients in AAV2 (Manno et al 2006) or AAV8 (Nathwani et al 2014) trials with the latest clearance of the vector observed at 12 weeks post-injection, quicker in younger men, but not in an AAV5 trial (D’Avola et al 2016). Vector was observed in seminal fluid but not in motile sperm and spermatogonia aligned with previous studies (Arruda et al 2001; Couto et al 2004).

Suboptimal animal models

The following examples demonstrate why animal experiments provide limited value for predicting effects in human trials:

- T-cell mediated cytotoxicity observed in the first haemophilia B trial was not predicted by experiments in mice, dogs or non-human primates (Pien et al 2009). Unlike research animals, humans are exposed to wild type AAV infections generating anti-AAV memory T cells, which are reactivated at the time of vector exposure (Mingozzi et al 2007).

- An over 80% rate of HCC was observed in a mouse model of methylmalonic acidemia injected neonatally with AAV2/8. Integration occurred in the Rian hotspot, a rodent-specific locus absent in other vertebrate genomes (Chandler et al 2015).

- The patterns of liver transgene expression in the hepatic lobule varies among different species. For example, using the AAV8 capsid, transgene expression is predominantly pericentral in mice and dogs and periportal in non-human primates (Fig. 4) (Bell et al 2011). This is of particular importance for liver diseases where metabolic zonation underpins that certain metabolic functions occur predominantly in certain areas of the liver lobule, which is the functional unit of the liver. For example, the urea cycle activity mostly takes place in periportal hepatocytes (Gebhardt and Matz-Soja 2014). To achieve adequate control of severe hyperammonaemia in the OTCD mouse model, therefore, requires a much higher than expected dose of AAV2/8 vector carrying OTC transgene, which might be explained by the non-physiological pattern of liver transduction (Cunningham et al 2011). Thus, it is difficult to reliably extrapolate vector doses for human translation from studies in mice in liver diseases with metabolic zonation like OTCD.

- AAV2/8 vectors are capable of transducing 100% hepatocytes in adult mice (Cunningham et al 2008), but data from human trials in haemophilia B have shown an increase in plasma FIX only 2 to 8% (Nienhuis et al 2016), suggesting much less efficient AAV2/8-mediated hepatocyte transduction in humans. Interestingly, most studies in a chimeric FRG (Fah<sup>−/−</sup>/Rag2<sup>−/−</sup>/Il2rg<sup>−/−</sup>) mouse-human liver model (Lisowski et al 2014; Wang et al 2015; Vercauteren et al 2016) showed that AAV3B and AAV3B-derived vectors (AAV3-ST, AAV-LK03) are able to transduce human hepatocytes approximately 10 times more efficiently than AAV2/8 whilst transduction of murine hepatocytes is minimal (Lisowski et al 2014).

The FRG mouse has a combination of tyrosinaemia type I and immunodeficiency phenotypes and is an attractive model to study human hepatocytes in vivo with the intention of overcoming limitations due to species-specificity (Azuma et al 2007). Human Fah<sup>−/−</sup> hepatocytes have a selective growth advantage relative to the Fah-deficient native mouse hepatocytes allowing human cell engraftment up to 90% of the liver mass (Azuma et al 2007). Moreover, this model can address disease-specific questions if engrafted with hepatocytes from patients with liver specific disorders. Recently, the even more complex FRGN (Fah<sup>−/−</sup>/Rag2<sup>−/−</sup>/Il2rg<sup>−/−</sup>/NOD) mouse model has been described in which FRG mice, developed in a non-obese diabetic (NOD) mouse strain, are simultaneously co-transplanted with human hepatocytes and human haematopoietic stem cells (Wilson et al 2014).

Limited capacity of AAV vectors

The single-stranded AAV vector can accommodate a transgene cassette of approximately 4.6 to 5 kb (Hirsch et al 2016). This capacity is reduced by half (2.3 kb) in self-complementary (i.e double-stranded) vectors. This is a major limitation compared to non-viral or other common viral vectors like lentiviral/recombinant viral vectors (up to at least 14 kb (Counsell et al 2017)) or helper-dependent adenoviruses (up to at least 38.9 kb (Suzuki et al 2011)). To deliver oversized transgenes, several approaches have been developed. Designing mini-promoters or mini-genomes of interest can be effective (Yan et al 2015). Alternatively, dual AAV co-transduction has been successfully tested either with split AAV or fragment AAV (Hirsch et al 2016). Split AAVs use the inherent tendency for intermolecular genome association observed with AAV genomes via either homologous recombination (HR) or non-homologous end joining (NHEJ) to produce concatemers. The overlapping approach uses vectors A and B, which display a homology sequence to promote intermolecular homologous recombination (Duan et al 2001; Koo et al 2014). In the trans-splicing approach, two splice sites in 3′ cDNA of vector A and 5′ cDNA of vector B are recognised in concatemerized provirus to generate the single DNA molecule of the oversized gene of interest (Duan et al 2001). A combination of the two approaches is known as the hybrid trans-splicing technique (Trapani et al 2014). In fragment AAV, the transgene is not entirely encapsidated but only fragments of different size, which can recombine on overlapping regions (Hirsch et al 2016). A limitation common to these approaches is reduced functional transduction efficiency.
Limited manufacturing capability

For the last couple of years, the rise in demand for good-manufacturing practice (GMP) AAV vectors for preclinical and clinical studies has created a bottleneck, delaying a number of projects. The industry is progressively taking up the gauntlet and developing improved and innovative methods for vector production in larger bioreactors with optimised reagents, purification techniques and packaging cell lines (Clement and Grieger 2016; Grieger et al. 2016).

Gene therapy requires an innovative economic model for success in modern healthcare

Patients with inherited metabolic disorders individually impose a much heavier financial burden on the healthcare system compared to the average person. For example, the lifetime cost for methylmalonic/propionic acidemias and Gaucher disease is $1.5 and 5 million, respectively (Li et al. 2015; Orkin and Reilly 2016). Gene therapy has the potential to achieve substantial savings. For example, a haemophilia B trial has shown that single injection of the gene therapy product in a cohort of ten patients can save more than $2.5 million over three years for the healthcare system in the UK (Nathwani et al. 2014).

It is likely that to recover the investment in product development, companies will need pricing gene therapy treatments ambitiously when their products reach market. However, the cost of treatment will need to be affordable for public healthcare systems. The first gene therapy product approved by the European Medicines Agency (EMA), Glybera®, is marketed by Uniqure. This drug has been in development for 8 years, with the initial developer going bankrupt and a currently proposed market cost of $1.2 million per patient (Bryant et al. 2013). GlaxoSmithKline’s Strimvelis® is the second gene therapy product to reach the market and was approved by the EMA in 2016. This gene therapy product, which targets ADA-SCID has been in development for over 16 years and the proposed cost is $665,000 per patient (Hoggatt 2016; Schimmer and Breazzano 2016).

Over the last 20 years, greater than $4.3 billion have been spent on development of gene therapy technology and return on this investment is still awaited (Ledley et al. 2014). Although most of the gene therapy programmes remain in the early stages of development, healthcare economists are generating models to cost treatments, which might provide lifelong cures. A pay-for-performance system has been proposed with yearly-capped annuity paid to the pharmaceutical company if criteria of a metabolic control of the disease are met (Touchot and Flume 2015). These criteria might reflect cost-effectiveness and not only cost-saving. This approach values the gain in quality of life estimated by quality-adjusted life years (QALY) analysis, which includes many parameters such as lifespan and ability to work (Orkin and Reilly 2016). Vouchers systems with longer financial incentives might be another option (Schimmer and Breazzano 2016).

In parallel, the regulatory framework is evolving with the progress of technology and the increasing experience being gathered from human trials. The Food and Drug Administration (FDA) and the EMA have published recommendations for gene therapy products (Narayanan et al. 2014). The need for shorter and less expensive paths to clinical trials and conditional approval relying more on human data for safety and efficacy has now been recognised, as exemplified by the FDA’s Breakthrough Therapies programme and the EMA’s Adaptive Pathways and Priority Medicines (PRIME) schemes which were launched in 2012, 2014 and 2016, respectively (Mullard 2016). These more flexible pathways will need to be agreed by government funding bodies (Macaulay 2015).

Considerations for paediatric application

Paediatric administration of gene therapy has several theoretical advantages (McKay et al. 2011). These include prevention of early death or irreversible neurological sequellae, transduction of stem/progenitor cells and possible avoidance of immune response as neonates have an immature immune system, while infants and children have lower rates of pre-existing anti-AAV immunity. The potential for even earlier gene therapy intervention has been explored in late gestation foetal macaques by intrahepatic injection of scAAV2/8 and scAAV2/5 vectors. Plasma human FIX levels of 8–112% were observed during a median follow-up period of 14 months without evidence hotspot integration and HCC (Mattar et al. 2011).

There is a theoretical risk, however, of increased tumorigenicity in the developing liver as observed in experiments performed in neonatal mice (Donsante et al. 2007; Chandler et al. 2015). A further challenge in the paediatric liver is the likely progressive loss of vector genomes over time in concert with hepatocellular proliferation. More than 90% of the AAV-delivered transgene cassettes exists as non-integrated episomes (Cunningham et al. 2008). The human liver weight doubles at 4 months, 16 months, 6 years and 12 years of age, which means that the adult liver is 16 times heavier than the neonatal liver (Coppoletta and Wolbach 1933; Sunderman and Boemer 1949). Therefore, it is unlikely that a neonatal injection will be sufficient to provide lifelong correction of the phenotype in metabolic liver diseases, with reinjection during the phase of rapid liver growth likely to be necessary.

An alternative approach to reinjection could be the use of integrating vectors and or locus-specific genome engineering. Sangamo Therapeutics Inc. is developing tools for transgene integration into the albumin locus and uses zinc finger
nucleases coupled with AAV technology. Other genome editing tools have been successfully tested with AAV vectors in a neonatal OTC deficiency mouse model. In these experiments, two AAV vectors were injected simultaneously, one of which encoded the transgene and the other the enzymatic system for integration or site specific cutting by Piggybac transposase (Cunningham et al 2015) and CRISPR-Cas9 (Yang et al 2016), respectively.

**Muscle-directed gene therapy for liver monogenic disorders**

Muscle-directed gene therapy has been developed for liver monogenic disorders with secreted protein such as haemophilia A and B and α1-antitrypsin deficiency. Intramuscular injections might circumvent some caveats observed with systemic injection, the common route of delivery for liver-targeted gene therapy: limited biodistribution with reduced risk of germline transmission, minimal exposure to circulating neutralising antibodies, reduced dose of vector for a similar effect.

A proof of concept using AAV2 vectors in mice (Herzog et al 1997) and dogs (Herzog et al 1999) affected by haemophilia B paved the way for a clinical trial (Kay et al 2000; Manno et al 2003), which showed a safe profile with long-standing expression in some patients (Jiang et al, 2006a, b; Buchlis et al 2012) but only a mild increase in plasma factor IX around 1% (Manno et al 2003). Depending on the dose considered, dozens to hundreds of intramuscular injections are necessary, which makes this route particularly impractical. For instance, Manno et al administered between 10 to 90 injections per patients in lower limbs (Manno et al 2003). Similarly, a proof of concept in mice with haemophilia A has been reported (Mah et al 2003).

Three AAV-mediated clinical trials have been conducted for α1-antitrypsin deficiency. In this disorder, a plasma level of wild-type (M) α1-antitrypsin above 11 μM is considered reducing the risk of developing emphysema. A first trial based on an AAV2 capsid showed an acceptable safety profile with mild local reactions at the site of intramuscular injection (redness, tenderness, bruising) and a seroconversion against AAV2. Unfortunately, only one out of 12 patients demonstrated a minimal increase of plasma M α1-antitrypsin at 82 nM (Flotte et al 2004; Brantly et al 2006). Two other trials (phase I then phase II) were conducted with a vector based on AAV1 capsid known for its better muscle transduction compared to AAV2 (Flotte et al 2011). In both trials, minor side effects and a seroconversion against AAV1 were observed (Brantly et al 2009; Flotte et al 2011). A moderate infiltration of reactive T lymphocytes in muscle biopsies was noticed (Flotte et al 2011). Plasma levels of M α1-antitrypsin were still mild, although improving in the latest trial due to higher doses injected (412 to 694 nM in the highest dose group) but far from the targeted protective level of 11 μM (Flotte et al 2011).

**Conclusion**

Over the last decade, major discoveries in the understanding of viral vector biology have generated promising results in pioneering clinical trials for haemophilia B using AAV vectors. This has paved the way for a wider development of AAV-mediated gene therapy for monogenic liver disorders. Although several clinical, manufacturing and economic challenges remain, this approach to treatment for severely debilitating diseases generated widespread enthusiasm shared by clinicians, researchers and investors alike. Gene transfer technologies are reaching an exciting threshold of efficacy and promise to revolutionise the management of many currently untreatable diseases.

**Compliance with ethical standards**

**Conflict of interest** J. Baruteau, S. N. Waddington, I. E. Alexander, and P. Gissen declare that they have no conflict of interest.

**Funding** J.B. is funded by Action Medical Research for Children Charity (grant GN2137) and Great Ormond Street Hospital (GOSH) Children’s Charity Clinical Research Starter Grant. J.B., S.N.W. and P.G. are in receipt of the UK Medical Research Council (MRC) grant MR/N019075/1. S.N.W. is funded by the MRC grants MR/N026101/1 and MR/P026494/1.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

Alba R, Bosch A, Chillón M (2005) Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 12(Suppl 1):S18–S27

Andrews JL, Kadan MJ, Gorziglia MI, Kaleko M, Connelly S (2001) Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol Ther 3:329–336

Angelis A, Tordrup D, Kanavos P (2015) Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy 119:964–979

Annoni A, Goudy K, Akharpour M, Naldini L, Roncarolo MG (2013) Immune responses in liver-directed lentiviral gene therapy. Transl Res 161:230–240

Apolonia L, Waddington SN, Fernandes C et al (2007) Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 15:1947–1954

Armstrong EP, Malone DC, Krishnan S, Wessler MJ (2014) Costs and utilization of hemophilia a and B patients with and without inhibitors. J Med Econ 17:798–802
Chua MK, Jackson CS, Oprea I et al (2015) Progresses towards safe and efficient gene therapy vectors. Oncotarget 6:30675–30703

Choudhury SR, Fitzpatrick Z, Harris AF et al (2016) In vivo selection yields AAV-B1 capsid for central nervous system and muscle Gene therapy. Mol Ther 24:1247–1257

Chua MA, Collen D, VandenDriessche T (2004) Clinical gene transfer studies for hemophilia a. Semin Thromb Hemost 30:249–256

Cideciyan AV, Aleman TS, Boye SL et al (2008) Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 105:15112–15117

Clayton PT (2002) Inborn errors presenting with liver dysfunction. Semin Neonatol 7:49–63

Clement N, Grieger JC (2016) Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev 3:16002

Conditti R, Goldenberg D, Giladi H et al (2014) Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature. Mol Ther 22:59–68

Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW (2009) Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum Gene Ther 20:767–776

Coppolletta JM, WolkHB SB (1933) Body length and organ weights of infants and children: a study of the Body length and normal weights of the more important vital organs of the Body between birth and twelve years of age. Am J Pathol 9:55–70

Corri M, Elder M, Falk D et al (2014) B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev 1:14035

Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, Waddington SN, Thrasher AJ, Muntoni F, Morgan JE, Danos O (2017) Lentiviral vectors can be used for full-length dystrophin gene therapy. Sci Rep 7:79

Couto L, Parker A, Gordon JW (2004) Direct exposure of mouse spermatocytes to very high concentrations of a serotype-2 adenov-associated virus gene therapy vector fails to lead to germ cell transduction. Hum Gene Ther 15:287–291

Crane B, Luo X, Demaster A et al (2012) Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia. Gene Ther 19:443–452

Cunningham SC, Dane AP, Spinoulas A, Logan GJ, Alexander IE (2008) Gene delivery to the juvenile mouse liver using AAV-2/8 vectors. Mol Ther 16:1081–1089

Cunningham SC, Kok CY, Dane AP et al (2011) Induction and prevention of severe hyperammonemia in the splash mouse model of omithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery. Mol Ther 19:854–859

Cunningham SC, Siew SM, Hallworth CV et al (2015) Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyBac transposase gene delivery system. Hepatology 62:417–428

D’Avola D, Lopez-Franco E, Sangro B et al (2016) Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol 65:776–783

Deverman BE, Pravdo PL, Simpson BP et al (2016) Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 34:204–209

Dhawan A, Mitry RR, Hughes RD (2006) Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 29:431–435

Doekecke A, Kromer A, Scherer MN, Schlitt HJ, Geissler EK (2010) AAV plasmid DNA simplifies liver-directed in vivo gene therapy: comparison of expression levels after plasmid DNA-, adeno-associated virus- and adeno-associated virus-mediated liver transfection. J Gene Med 12:810–817

Dolgin E (2016) Early clinical data raise the bar for hemophilia gene therapies. Nat Biotechnol 34:999–1001

Donsante A, Miller DG, Li Y et al (2007) AAV vector integration sites in mouse hepatocellular carcinoma. Science 317:477

Duan D, Yue Y, Engelhardt JF (2001) Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 4:383–391

Earley LF, Powers JM, Adachi K et al (2017) Adeno-associated virus (AAV) assembly-activating protein is not an essential requirement for capsid assembly of AAV serotypes 4, 5, and 11. J Virol 91: e01980-16

Ehrhardt A, Kay MA (2002) A new adenoassociated helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99:3923–3930

Ehrhardt A, Xu H, Dillow AM, Bellinger DA, Nichols TC, Kay MA (2003) A gene-deleted adeno-associated viral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 102:2403–2411

Elsabhhy M, Nazanali A, Foldvari M (2011) Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv 8:235–244

Fabs SA, Hille MT, Shi Q, Weiler H, Montgomery RR (2014) A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123:3706–3713

Fischer A, Hacine-Bey-Ahina S, Cavazzana-Calvo M (2010) 20 years of gene therapy for SCID. Nat Immunol 11:457–460

Flanigan KM, Campbell K, Violett L et al (2013) Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 24:797–806

Flotte TR, Brantly ML, Spencer LT et al (2004) Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-HAAT) gene vector to AAT-deficient adults. Hum Gene Ther 15:93–128

Flotte TR, Trapnell BC, Humphries M et al (2011) Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 22:1239–1247

Fumoto S, Kawakami S, Hashida M, Nishida K (2013) Targeted gene delivery: importance of administration routes. In: Good D, Wei M (eds.) Novel gene therapy approaches. doi: 10.5772/54741

Gao GP, Yang Y, Wilson JM (1996) Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 70:8934–8943

Gebhardt R, Matz-Soja M (2014) Liver zonation: novel aspects of its regulation and its impact on homeostasis. World J Gastroenterol 20:8491–8504

George L, Sullivan S, Giemnasz A (2016) Adeno-associated virus mediated gene transfer for Hemophilia B achieves sustained mean factor IX activity levels of>30% without immunosuppression. 58th annual meeting of the American Society of Hemophelia

Gil-Farina I, Schmidt M (2016) Interaction of vectors and parental viruses with the host genome. Curr Opin Virol 21:35–40

Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J (2013) Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 15:65–77

Gramignoli R, Vosough M, Kannisto K, Srinivasan RC, Strom SC (2015) Clinical hepatocyte transplantation: practical limits and possible solutions. Eur Surg Res 54:162–177

Grieger JC, Soltys SM, Samulski RJ (2016) Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther 24:287–297

Grossman M, Raper SE, Kozarsky K et al (1994) Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nat Genet 6:335–341
Mann CS, Chew AJ, Hutchinson S et al (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963–2972
Mann CS, Pierce GF, Arruda VR et al (2006) Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 12:342–347
Matar CN, Nathwani AC, Waddington SN et al (2011) Stable human factor expression after 0.9G intratissue gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques. Mol Ther 19:1950–1960
Mayrhofer P, Schleef M, Jeclinger W (2009) Use of minicircle plasmids for gene therapy. Methods Mol Biol 542:87–104
McCarty DM (2004) Self-complementary AAV vectors; advances and applications. Mol Ther 16:1648–1656
McCarty DM, Young SM Jr, Samulski RJ (2004) Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38:819–845
McCormack WM Jr, Seiler MP, Bertin TK et al (2006) Helper-dependent adeno viral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia a model. J Thromb Haemost 4:1218–1225
McCarrity GJ, Hoyah G, Winemiller A et al (2013) Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med 15:78–82
McIntosh JH, Cochrane M, Cobbold S et al (2012) Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther 19:78–85
McCay TR, Rahim AA, Buckley SM et al (2011) Perinatal gene transfer to the liver. Curr Pharm Des 17:2528–2541
Mian A, Lee B (2002) Urea-cycle disorders as a paradigm for inborn errors of hepatocyte metabolism. Trends Mol Med 8:583–589
Miesbach W, Tangelder M, Klamroth R (2016) Updated results from a phase 1 trial of BAX335, an adeno-associated virus assembly-activating protein. J Virol 86:13038–13048
Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72:8150–8157
Monahan PE, Lothrop CD, Sun J et al (2010) Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther 18:1905–1916
Monahan P, Walsh C, Powell J (2015) Update on a phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B. J Thromb Haemost 13(Suppl 2):E7
Monteilhet V, Sahel S, Boutin S et al (2011) A 10 patient case report on the impact of phasemorphases upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther 19:2084–2091
Morral N, O’Neal W, Rice K et al (1999) Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in ba- boons. Proc Natl Acad Sci USA 96:12816–12821
Morral N, O’Neal WK, Rice K et al (2002) Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adeno viral vector in baboons. Hum Gene Ther 13:143–154
Mukherjee S, Thrasher AJ (2013) Gene therapy for PIDs: progress, pitfalls and prospects. Gene 525:174–181
Mullard A (2016) European regulators launch “breakthrough” equivalent programme. Nat Rev Drug Discov 15:223
Muruve DA, Cotter MJ, Zaiss AK et al (2004) Helper-dependent adeno virus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78:5966–5972
Narayanan G, Cosso G, Galli MC et al (2014) Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union. Hum Gene Ther Clin Dev 25:1–6
Nathwani AC, Gray JT, McIntosh J et al (2007) Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109:1414–1421
Nathwani AC, Rosales C, McIntosh J et al (2011) Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 19:876–885
Nathwani AC, Reiss UM, Tuddenham EG et al (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371:1994–2004
Nault JC, Datta S, Imbeaud S et al (2015) Recurrent AAV2-related insertional mutagenesis in human hematopoietic carcinomas. Nat Genet 47:1187–1193
Naumr M, Sonntag F, Schmidt K et al (2012) Properties of the adeno-associated virus assembly-activating protein. J Virol 86:13038–13048
Nguyen TH, Mainot S, Lainas P et al (2009) Ex vivo liver-directed gene therapy for the treatment of metabolic diseases: advances in hepatocyte transplantation and retroviral vectors. Curr Gene Ther 9:136–149
Nienhuis AW, Nathwani AC, Davidoff AM (2016) Gene therapy for hemophilia. Hum Gene Ther 27:305–308
Nightingale SJ, Hollis RP, Pepper KA et al (2006) Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 13:1121–1132
Nomura S, Merched A, Nour E, Dieker C, Oka K, Chan L (2004) Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther 11:1540–1548
Nowrouzi A, Cheung WT, Li T et al (2013) The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis. Mol Ther 21:324–337
Oishi Y, Kakimoto T, Yuan W, Kuno S, Yamashita H, Chiba T (2016) Fetal Gene therapy for ornithine Transcarbamylase deficiency by intrahepatic plasmid DNA-micro-bubble injection combined with hepatic ultrasound Insonation. Ultrasound Med Biol 42:1357–1361
Orkin SH, Motulsky AG (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy. National Institute of Health, Bethesda
Orkin SH, Reilly P (2016) MEDICINE. Paying for future success in gene therapy. Science 352:1059–1061
Pasi J, Wong W, Rangarajan S (2016) Interim results of an open-label, phase 1/2 study of BMN 270, an AAV5-FVIII gene transfer in severe hemophilia a. Haemophilia 22:151
Perrin GQ, Zolotukhin I, Sherman A et al (2016) Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer. Mol Ther Methods Clin Dev 3:16083
Philippe S, Sarkis C, Barkats M et al (2006) Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 103:17684–17689

Piccolo P, Brunetti-Pierri N (2014) Challenges and prospects for helper-dependent adenoviral vector-mediated gene therapy. Biomedicine 2:132–148

Pien GC, Basner-Tschakarjan E, Hui DJ et al (2009) Capsid antigen presentation flags human hepatocytes for destruction after transduction by adenovirus-associated viral vectors. J Clin Invest 119:1688–1695

Pillay S, Meyer NL, Puschnik AS et al (2016) An essential receptor for adenovirus-associated virus infection. Nature 530:108–112

Powell JS, Ragni MV, White GC 2nd et al (2003) Phase 1 trial of FVIII gene transfer for severe hemophilia a using a retroviral construct administered by peripheral intravenous infusion. Blood 102:2038–2045

Puulmalainen AM, Vapalahti M, Agrawal RS et al (1998) Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 9:1769–1774

Rabinowitz JE, Rolling F, Li C et al (2002) Cross-packaging of a single replication-deficient retrovirus and adenovirus. Hum Gene Ther 16:509

Raper SE, Haskal ZJ, Ye X et al (1998) Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses. Hum Gene Ther 9:671–679

Ration AA, Wong AM, Howe SJ et al (2009) Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther 16:509–520

Raper SE, Grossman M, Rader DJ et al (1996) Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg 223:116–126

Raper SE, Haskal ZJ, Ye X et al (1998) Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses. Hum Gene Ther 9:671–679

Raper SE, Yudkoff M, Chirmule N et al (2002) A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial omithine transcarbamylase deficiency. Hum Gene Ther 13:163–175

Raper SE, Chirmule N, Lee FS et al (2003) Fatal systemic inflammatory response syndrome in a omithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148–158

Rastall DP, Seregin SS, Aldhamen YA et al (2016) Long-term, high-level hepatic secretion of acid alpha-glucosidase for Pompe disease achieved in non-human primates using helper-dependent adenovirus. Gene Ther 23:743–752

Reddy PS, Sakhuja K, Ganesh S et al (2002) Sustained human factor VIII expression in hemophilia a mice following systemic delivery of a gutless adenoviral vector. Mol Ther 5:63–73

Rosewell Shaw A, Suzuki M (2016) Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol 21:9–15

Samulski RJ, Muzychka N (2014) AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 1:427–451

Sarkar R, Mucci M, Addya S et al (2006) Long-term efficacy of adenovirus vector serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther 17:427–439

Schiedner G, Bloch W, Hertel S et al (2016) A hemodynamic response to defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 103:17684–17689

Schimmer J, Breazzano S (2016) Investor outlook: solving gene therapy–virus therapies for cancer. Curr Opin Virol 21:9

Shi Y, Falahati R, Zhang J, Flebbe-Rewaldt L, Gaensler KM (2013) Role of antigen-specific regulatory CD4+CD25+ T cells in tolerance induction after neonatal IP administration of AAV-hFIX. Gene Ther 20:987–996

Sokal EM (2006) Liver transplantation for inborn errors of liver metabolism. J Inherit Metab Dis 29:426–430

Spada M, Riva S, Maggiore G, Cintorino D, Gridelli B (2009) Pediatric liver transplantation. World J Gastroenterol 15:648–674

Stephen SL, Montini E, Sivanandam VG et al (2010) Chromosomal integration of adenoviral vector DNA in vivo. J Virol 84:9987–9994

Summerford C, Samulski RJ (2016) AAVR: a multi-serotype receptor for AAV. Mol Ther 24:663–666

Sunderman FW, Boerner F (1949) Normal value in clinical medicine. Saunders, Philadelphia

Suvannamee T, Hu G, Gui T et al (2014) Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in hemophilia B mice. Mol Ther 22:567–574

Suzuki T, Sasaki T, Yano K et al (2011) Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome. Virus Res 158:154–160

Suzuki M, Bertin TK, Rogers GL et al (2013) Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adenovirus-associated viral vectors in vivo. Mol Ther 21:796–805

Tang J, Olive M, Pulmanausahakul R et al (2006) Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 350:312–322

Thaci B, Ulasov IV, Wainwright DA, Lesniak MS (2011) The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2:113–121

Thwaite R, Pages G, Chilllon M, Bosch A (2015) AAVh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. Gene Ther 22:196–201

Toietta G, Mane VP, Norona WS et al (2005) Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 102:3930–3935

Touchot N, Flume M (2015) The payers’ perspective on gene therapies. Nat Biotechnol 33:902–904

Trapani I, Colella P, Sommella A et al (2014) Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med 6:194–211

Tse LV, Moller-Tank S, Asokan A (2015) Strategies to circumvent human immune response to adenovirus. Expert Opin Biol Ther 15:845–855

Tseng YS, Agbandje-McKenna M (2014) Mapping the AAV capsid host antibody response toward the development of second generation Gene delivery vectors. Front Immunol 5:9

Utna C, Sampredo A, Mauleon I et al (2013) Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice. Hum Gene Ther 24:1042–1049

Vercauteren K, Hoffman BE, Zolotukhin I et al (2016) Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther 24:1042–1049

Verma IM, Sivia N (1997) Gene therapy - promises, problems and prospects. Nature 389:239–242

Viecelli HM, Harbottle RP, Wong SP et al (2014) Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver. Hepatology 60:1035–1043

Vigant F, Descamps D, Julienne B et al (2008) Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16:1474–1480
Waddington SN, McVey JH, Bhella D et al (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397–409

Wang L, Bell P, Somanathan S et al (2015) Comparative study of liver Gene transfer with AAV vectors based on natural and engineered AAV capsids. Mol Ther 23:1877–1887

White GI, Monahan PE (2005) Gene therapy for hemophilia a. In: Lee CR, Bern trop E, Hoots K (eds) Textbook of hemophilia. Blackwell, Oxford, pp 226–228

Wilson JM (2009) Lessons learned from the gene therapy trial for omithine transcarbamylase deficiency. Mol Genet Metab 96:151–157

Wilson EM, Bial J, Tarlow B et al (2014) Extensive double humanization of both liver and hematopoiesis in FRGN mice. Stem Cell Res 13:404–412

Wirth T, Parker N, Yla-Herttuala S (2013) History of gene therapy. Gene 525:162–169

Wold WS, Toth K (2013) Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13:421–433

Wolff JA, Budker V (2005) The mechanism of naked DNA uptake and expression. Adv Genet 54:3–20

Wu X, Liu G, Mu M et al (2016) Augmenter of liver regeneration gene therapy using a novel minicircle DNA vector alleviates liver fibrosis in rats. Hum Gene Ther 27:880–891

Yan Z, Sun X, Feng Z et al (2015) Optimization of recombinant adenassociated virus-mediated expression for large transgenes, using a synthetic promoter and tandem array enhancers. Hum Gene Ther 26:334–346

Yang Y, Ertl HC, Wilson JM (1994) MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1:433–442

Yang Y, Wang L, Bell P et al (2016) A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol 34:334–338

Yokoo T, Kamimura K, Abe H et al (2016) Liver-targeted hydrodynamic gene therapy: recent advances in the technique. World J Gastroenterol 22:8862–8868

Zaiss AK, Muruve DA (2008) Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 15:808–816

Zhang HG, Zhou T, Yang P, Edwards CK 3rd, Curiel DT, Mountz JD (1998) Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther 9:1875–1884

Zhu J, Huang X, Yang Y (2007) Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 81:3170–3180

Zufferey R, Dull T, Mandel RJ et al (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873–9880